This study is currently not recruiting participants.

Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures

Study Comparing Safety and Effectiveness of Investigational Medications for Osteoporosis in Postmenopausal Women

Not Recruiting
45 years - 100 years
Female
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to compare the safety of teriparatide and risedronate and how well they will work to help postmenopausal osteoporotic women who have osteoporotic spine fractures.

Detailed description of study

The primary objective of this study is to evaluate if teriparatide 20 ?g subcutaneously once daily is superior in reducing the incidence of new vertebral fractures during 24 months of therapy, when compared with risedronate 35 mg orally once weekly, in postmenopausal women with prevalent vertebral fragility fractures.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: osteoporosis
  • Age: 45 years - 100 years
  • Gender: Female

This study investigates the safety and effectiveness of two investigational medications in postmenopausal women with osteoporosis who have spine fractures. Osteoporosis is a condition where bones become weak and are more likely to break. The purpose of the study is to see if one medication is better than the other in preventing new spine fractures over a period of time.

Participants in the study will receive either an investigational medication given as a daily injection or another investigational medication taken as a weekly pill. The study will monitor the occurrence of new vertebral fractures to determine which treatment is more effective.

  • Who can participate: Postmenopausal women aged X and above with osteoporosis and existing spine fractures are eligible to participate.
  • Study details: Participants will either receive a daily injection or a weekly pill. The study will compare the effects of these treatments on spine fractures. A placebo is not used in this study.
  • Study Timelines: The study will last 24 months.
Updated on 19 Feb 2024. Study ID: 1401219897

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team